In conclusion, our experimental results collectively establish SMR3B as a prognostic biomarker in both breast cancer and thyroid cancer, significantly restraining key oncogenic phenotypes including proliferation, migration, and invasion of cancer cells. This evidence concerns the gene SMR3B and breast carcinoma.